Torsten W.
- Country
- Germany
- Department
- #40024: Klinik für Rheumatologie und Immunologie
Research Overview
- Phase 1b Open-Label Evaluation of CLN-978 in Patients with Active Moderate to Severe Sjogren's Disease
- A Phase 3 Randomized Controlled Trial to Evaluate the Efficacy and Safety of Rilzabrutinib in Adults with Active IgG4-Related Disease
- A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period
Data & Insights
Has run more than one trial at 140 of 336 partner sites.
Specializations
Autoimmune Rheumatic Conditions
The investigator specializes in treating Sjögren's syndrome and systemic lupus erythematosus, focusing on innovative therapeutic approaches for these complex autoimmune disorders.
- Primary Sjögren's syndrome management
- SLE treatment strategies
- Novel biologic therapies
Particular emphasis is placed on evaluating long-term treatment outcomes and systemic manifestations of these conditions.
Inflammatory Arthritis
Clinical expertise extends to treating psoriatic arthritis and axial spondyloarthritis, with a focus on biologic disease-modifying therapies.
- Advanced psoriatic arthritis treatments
- Axial spondyloarthritis management
- Biologic therapy assessment
The investigator works with both treatment-naive patients and those with inadequate response to conventional therapies.
Rare Inflammatory Disorders
Specialized focus on treating giant cell arteritis and dermatomyositis, incorporating emerging therapeutic options for these challenging conditions.
- Giant cell arteritis treatment protocols
- Dermatomyositis management strategies
- Immunomodulatory approaches
Treatment strategies emphasize both disease control and reduction of corticosteroid dependence.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.